2-47799221-G-C
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000179.3(MSH6):c.1238G>C(p.Trp413Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. W413C) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000179.3 missense
Scores
Clinical Significance
Conservation
Publications
- intellectual developmental disorder with dysmorphic facies and behavioral abnormalitiesInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000179.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH6 | NM_000179.3 | MANE Select | c.1238G>C | p.Trp413Ser | missense | Exon 4 of 10 | NP_000170.1 | ||
| MSH6 | NM_001406795.1 | c.1334G>C | p.Trp445Ser | missense | Exon 5 of 11 | NP_001393724.1 | |||
| MSH6 | NM_001406813.1 | c.1244G>C | p.Trp415Ser | missense | Exon 4 of 10 | NP_001393742.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH6 | ENST00000234420.11 | TSL:1 MANE Select | c.1238G>C | p.Trp413Ser | missense | Exon 4 of 10 | ENSP00000234420.5 | ||
| MSH6 | ENST00000445503.5 | TSL:1 | n.*585G>C | non_coding_transcript_exon | Exon 3 of 9 | ENSP00000405294.1 | |||
| MSH6 | ENST00000445503.5 | TSL:1 | n.*585G>C | 3_prime_UTR | Exon 3 of 9 | ENSP00000405294.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change replaces tryptophan, which is neutral and slightly polar, with serine, which is neutral and polar, at codon 413 of the MSH6 protein (p.Trp413Ser). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of Lynch syndrome (internal data). ClinVar contains an entry for this variant (Variation ID: 237131). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt MSH6 protein function with a positive predictive value of 95%. This variant disrupts the p.Trp413 amino acid residue in MSH6. Other variant(s) that disrupt this residue have been observed in individuals with MSH6-related conditions (external communication, internal data), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.W413S variant (also known as c.1238G>C), located in coding exon 4 of the MSH6 gene, results from a G to C substitution at nucleotide position 1238. The tryptophan at codon 413 is replaced by serine, an amino acid with highly dissimilar properties. This variant has been identified in probands whose Lynch syndrome-associated tumor demonstrated high microsatellite instability (MSI-H) and loss of MSH6 expression by immunohistochemistry (IHC; Li S et al. J. Med. Genet. 2020 Jan;57:62-69; Hájková N et al. Transl Res, 2023 Oct;260:61-68; Ambry internal data). In addition, this variant has been identified in probands whose Lynch syndrome-associated tumor was microsatellite stable (MSS) or MSI-L but demonstrated partial loss of MSH2/MSH6 or MSH6 expression by IHC, respectively (Kiyozumi Y et al. Cancer Epidemiol Biomarkers Prev, 2021 Jan;30:166-174). Another variant at the same codon, p.W413C (c.1239G>C), has been identified in individuals with features consistent with MSH6-related Lynch syndrome (Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at